联合应用人淋巴母细胞干扰素-α和西咪替丁治疗晚期肾细胞癌。

Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.

机构信息

Department of Urology, Center for Adult Diseases, Osaka, Japan.

出版信息

Int J Urol. 1996 Jan;3(1 Suppl):S41-3. doi: 10.1111/j.1442-2042.1996.tb00083.x.

DOI:10.1111/j.1442-2042.1996.tb00083.x

Abstract

Human lymphoblastoid interferon (IFN)-alpha was administered intramuscularly at doses of 5 megaunits/day 5 to 7 days a week to 32 advanced renal cell carcinoma patients. To augment the antitumor effect of IFN, cimetidine was also administered orally in doses oi 800 mg/day. This combination therapy resulted in a complete response (CR) in 6 patients (19%), a partial response (PR) in 7 (22%), a stable disease (SD) in 11 (34%), and a progressive disease (PD) in 8 (25%). The response rate (CR+PR) was 41%. The pulmonary metastases were more receptive to IFN therapy than those at other sites. The median times to response were 2 months for PR, and 4.5 months for CR. The survival of the responder patients was significantly longer than the nonresponder patients. These results suggest that IFN-alpha and cimetidine combination therapy may be of use in the management of advanced renal cell carcinoma.

摘要

人淋巴母细胞干扰素（IFN）-α每周 5 至 7 天，每天 5 兆单位肌内给予 32 例晚期肾细胞癌患者。为增强 IFN 的抗肿瘤作用，还每天口服西咪替丁 800mg。该联合治疗使 6 例患者（19%）完全缓解（CR），7 例（22%）部分缓解（PR），11 例（34%）病情稳定（SD），8 例（25%）病情进展（PD）。反应率（CR+PR）为 41%。肺转移对 IFN 治疗的反应性高于其他部位。PR 的中位反应时间为 2 个月，CR 为 4.5 个月。应答者的生存时间明显长于无应答者。这些结果表明，IFN-α和西咪替丁联合治疗可能对晚期肾细胞癌的治疗有用。